Cargando…

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

IMPORTANCE: Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the bayesian approach will only continue to increase. Innovations possible when using the bayesian approach improve the efficiency of drug development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berry, Donald A., Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J., Irizarry, Michael, Kramer, Lynn D., Berry, Scott M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091161/ https://www.ncbi.nlm.nih.gov/pubmed/37040116 http://dx.doi.org/10.1001/jamanetworkopen.2023.7230

Ejemplares similares

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
por: Dhadda, Shobha, et al.
Publicado: (2022)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
por: McDade, Eric, et al.
Publicado: (2022)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial
por: Broglio, Kristine, et al.
Publicado: (2022)

Lecanemab en la enfermedad de Alzheimer: ¿realmente estamos ante un cambio en el pronóstico de la enfermedad?
por: Pérez-Martínez, David A.
Publicado: (2023)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

A Bayesian Framework for Generalized Linear Mixed Modeling Identifies New Candidate Loci for Late-Onset Alzheimer’s Disease
por: Wang, Xulong, et al.
Publicado: (2018)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Bayesian optimization for demographic inference
por: Noskova, Ekaterina, et al.
Publicado: (2023)

Subgroup‐specific dose finding for phase I‐II trials using Bayesian clustering
por: Curtis, Alexandra, et al.
Publicado: (2022)

Deciphering Sex-Specific Genetic Architectures Using Local Bayesian Regressions
por: Funkhouser, Scott A., et al.
Publicado: (2020)

Genomic Bayesian Confirmatory Factor Analysis and Bayesian Network To Characterize a Wide Spectrum of Rice Phenotypes
por: Yu, Haipeng, et al.
Publicado: (2019)

Bayesian Networks Predict Neuronal Transdifferentiation
por: Ainsworth, Richard I., et al.
Publicado: (2018)

The Blinded-Dose Purchase Task: assessing hypothetical demand based on cocaine, methamphetamine, and alcohol administration
por: Berry, Meredith S., et al.
Publicado: (2023)

Validated Bayesian Differentiation of Causative and Passenger Mutations
por: Cross, Frederick R., et al.
Publicado: (2017)

A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
por: Xu, Jin, et al.
Publicado: (2022)

A Bayesian Model for the Analysis of Transgenerational Epigenetic Variation
por: Varona, Luis, et al.
Publicado: (2015)

Bayesian Population Genomic Inference of Crossing Over and Gene Conversion
por: Padhukasahasram, Badri, et al.
Publicado: (2011)

Bayesian Estimation of Population Size Changes by Sampling Tajima’s Trees
por: Palacios, Julia A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_du5qsh9is7e8op19p1kmrmehhr